Tyme Technologies is a biotechnology company developing cancer metabolism-based therapies (CMBTs) that are intended to be effective across a range of solid tumors and hematologic cancers. Co. is focused on developing its compound, SM-88, as well as further evaluating its preclinical pipeline of CMBT™ programs, and TYME-19 as a potential therapeutic for SARS CoV-2 diseases. The TYME average annual return since 2015 is shown above.
The Average Annual Return on the TYME average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TYME average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TYME average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free TYME Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
